Dasatinib-induced pleural and pericardial effusion: A case report and review

Introduction: Tyrosine Kinase Inhibitors (TKI) have dramatically changed the prognostic of chronic myeloid leukemia. However, they have been associated with several side effects. Case report: We describe a case of a patient admitted for bilateral exudative pleural and pericardial effusions. After a complete work-up, we concluded to a dasatinib-related side effect. Management and outcome: The patient received oxygen supply, aerosols of ipratropium/salbutamol, and 50 mg of Prednisone for 5 days. The treatment by dasatinib was stopped. She remained asymptomatic at the two-month control by her haematologist. The chest xray showed a small remaining bilateral effusion. Discussion: Based on this case, we performed a literature review on the subject to give insight on the associated risk factors, treatment options and prognostic. Dasatinib-related pleural effusion is frequent, but most often asymptomatic. Further studies are needed to better understand its mechanism and help guide treatment.